Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 65862-547

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 65862-547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
A line chart showing the probability of achieving systolic blood pressure less than 140 mmHg at week 8, plotted against baseline systolic blood pressure values from 140 to 180 mmHg. Four treatment groups are compared: valsartan and hydrochlorothiazide 320 mg/25 mg (dotted line), valsartan 320 mg (triangle markers), hydrochlorothiazide 25 mg (square markers), and placebo (cross markers). Probability decreases as baseline systolic blood pressure increases for all groups, with the combination therapy showing the highest probability.*
FDA Label Image

Package Label-principal Display Panel (160 mg/25 mg Blister Carton (10 x 10 Unit-dose))

Package Label-principal Display Panel (160 mg/25 mg Blister Carton (10 x 10 Unit-dose))
Packaging label for Valsartan and Hydrochlorothiazide Tablets USP, 160 mg/25 mg, film-coated tablets. The label indicates a quantity of 100 (10 x 10) unit-dose tablets, produced by Aurobindo Pharma Limited. The label includes dosage strength and medication name prominently with a blue and green color scheme and the NDC 65862-549-10.*
FDA Label Image

Package Label-principal Display Panel (320 mg/12.5 mg (90 Tablets Bottle))

Package Label-principal Display Panel (320 mg/12.5 mg (90 Tablets Bottle))
Label for Valsartan and Hydrochlorothiazide Tablets USP, 320 mg/12.5 mg, film-coated tablets. The label shows a package containing 90 tablets manufactured by Aurobindo Pharma Limited and distributed by Aurobindo Pharma USA, Inc. It includes dosage information, storage instructions, and a barcode.*
FDA Label Image

Package Label-principal Display Panel (320 mg/25 mg (90 Tablets Bottle))

Package Label-principal Display Panel (320 mg/25 mg (90 Tablets Bottle))
Label for Valsartan and Hydrochlorothiazide Tablets, USP 320 mg/25 mg film-coated tablets by Aurobindo Pharma Limited. The package contains 90 tablets. Storage instructions specify 20° to 25°C (68° to 77°F) with protection from moisture and heat. Distributed by Aurobindo Pharma USA, Inc., made in India, with NDC 65862-551-90.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)
A line graph depicting the probability of achieving diastolic blood pressure below 90 mmHg versus baseline diastolic blood pressure (DBP) from 90 to 110 mmHg. It compares four groups: Valsartan and Hydrochlorothiazide 320 mg/25 mg combination (highest probability), Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo (lowest probability).*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)
A line graph showing the probability of achieving systolic blood pressure below 130 mmHg at week 8, comparing Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, plotted against baseline systolic blood pressure values from 140 to 180 mmHg.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)
A line graph depicting the probability of achieving diastolic blood pressure (DBP) below 80 mmHg at week 8. The x-axis represents baseline DBP (mmHg) ranging from 90 to 110, and the y-axis shows the percentage achieving DBP <80 mmHg from 0 to 100%. Four data series are shown: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by different markers in the legend.*
FDA Label Image

Valhyctz-fig5 (Valhyctz Fig5)

Valhyctz-fig5 (Valhyctz Fig5)
Label for Valsartan and Hydrochlorothiazide Tablets, USP, film-coated tablets with strength 80 mg/12.5 mg. The label states Rx only and indicates a package of 90 tablets. Distributed by Aurobindo Pharma USA, Inc., made in India, with storage instructions and dosage information references. Includes barcode and NDC number 65862-547-90.*
FDA Label Image

Package Label-principal Display Panel (80 mg/12.5 mg Blister Carton (10 x 10 Unit-dose))

Package Label-principal Display Panel (80 mg/12.5 mg Blister Carton (10 x 10 Unit-dose))
Packaging label for Valsartan and Hydrochlorothiazide Tablets, USP 80 mg/12.5 mg. The label shows a box containing 100 unit-dose film-coated tablets, marked for prescription use only. The labeler is Aurobindo Pharma Limited and includes dosing and packaging details with a barcode and NDC 65862-547-10.*
FDA Label Image

Package Label-principal Display Panel (160 mg/12.5 mg (90 Tablets Bottle))

Package Label-principal Display Panel (160 mg/12.5 mg (90 Tablets Bottle))
Label for Valsartan and Hydrochlorothiazide Tablets USP 160 mg/12.5 mg, film-coated tablets by Aurobindo Pharma Limited. The package contains 90 tablets and includes dosage strength, storage instructions, distributor and manufacturing details, and a barcode.*
FDA Label Image

Package Label-principal Display Panel (160 mg/12.5 mg Blister Carton (10 x 10 Unit-dose))

Package Label-principal Display Panel (160 mg/12.5 mg Blister Carton (10 x 10 Unit-dose))
Packaging label for Valsartan and Hydrochlorothiazide Tablets, USP, 160 mg/12.5 mg, film-coated tablets. The label indicates a package size of 100 unit-dose tablets (10 x 10). The labeler is Aurobindo Pharma Limited. The design includes the product name, strength, NDC 65862-548-10, and dosage form.*
FDA Label Image

Package Label-principal Display Panel (160 mg/25 mg (90 Tablets Bottle))

Package Label-principal Display Panel (160 mg/25 mg (90 Tablets Bottle))
Label for Valsartan and Hydrochlorothiazide Tablets USP 160 mg/25 mg film-coated tablets. The label indicates the product is for prescription use only and comes in a package of 90 tablets. Distributed by Aurobindo Pharma USA, Inc., the label specifies storage conditions and drug dosage instructions, with the product made in India.*
FDA Label Image

Chemical Structure1 (Valhyctz Str1)

Chemical Structure1 (Valhyctz Str1)
Chemical structure of Valsartan as part of the combination drug Valsartan and Hydrochlorothiazide. The diagram shows the molecular formula with distinct aromatic rings and side chains.*
FDA Label Image

Chemical Structure 2 (Valhyctz Str2)

Chemical Structure 2 (Valhyctz Str2)
Chemical structure diagram of the active ingredient Valsartan and Hydrochlorothiazide, showing its molecular arrangement with labeled atoms and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.